 David Kao
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 31 | 2023 | 1962 | 5.030 |
Why?
| | Stroke Volume | 16 | 2022 | 514 | 2.180 |
Why?
| | Machine Learning | 5 | 2022 | 315 | 1.900 |
Why?
| | Methadone | 5 | 2023 | 73 | 1.760 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 66 | 1.640 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 298 | 1.620 |
Why?
| | Buprenorphine | 3 | 2023 | 141 | 1.540 |
Why?
| | Cardiomyopathies | 5 | 2022 | 298 | 1.540 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 180 | 1.450 |
Why?
| | Pharmacogenetics | 5 | 2024 | 155 | 1.290 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 273 | 1.250 |
Why?
| | Electronic Health Records | 7 | 2024 | 809 | 1.210 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 26 | 1.100 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2023 | 339 | 1.090 |
Why?
| | Propanolamines | 3 | 2019 | 93 | 0.990 |
Why?
| | Torsades de Pointes | 4 | 2016 | 17 | 0.820 |
Why?
| | Telemedicine | 3 | 2020 | 669 | 0.790 |
Why?
| | Pulmonary Edema | 1 | 2021 | 112 | 0.780 |
Why?
| | Coffee | 1 | 2021 | 11 | 0.770 |
Why?
| | Stroke | 2 | 2021 | 1021 | 0.760 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 54 | 0.740 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 402 | 0.730 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 282 | 0.720 |
Why?
| | Humans | 78 | 2024 | 117047 | 0.710 |
Why?
| | Mobile Applications | 1 | 2021 | 144 | 0.690 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 73 | 0.670 |
Why?
| | Prosthesis Failure | 1 | 2020 | 118 | 0.670 |
Why?
| | Long QT Syndrome | 3 | 2016 | 61 | 0.670 |
Why?
| | Spironolactone | 1 | 2019 | 33 | 0.660 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 103 | 0.660 |
Why?
| | Device Removal | 1 | 2020 | 129 | 0.660 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 45 | 0.650 |
Why?
| | Medical Records | 2 | 2019 | 159 | 0.640 |
Why?
| | Coronary Disease | 1 | 2021 | 352 | 0.640 |
Why?
| | Mortality | 3 | 2019 | 291 | 0.630 |
Why?
| | Periodicals as Topic | 1 | 2020 | 184 | 0.620 |
Why?
| | Artificial Intelligence | 1 | 2019 | 145 | 0.620 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 792 | 0.600 |
Why?
| | United States | 19 | 2021 | 12379 | 0.600 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 46 | 0.590 |
Why?
| | Aged | 27 | 2022 | 19356 | 0.590 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 318 | 0.590 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 53 | 0.570 |
Why?
| | Risk Assessment | 7 | 2020 | 3021 | 0.570 |
Why?
| | Hospital Records | 1 | 2016 | 11 | 0.560 |
Why?
| | Proteoglycans | 1 | 2017 | 109 | 0.550 |
Why?
| | Hospitalization | 9 | 2021 | 1762 | 0.550 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.530 |
Why?
| | Female | 43 | 2022 | 60630 | 0.520 |
Why?
| | Survival | 1 | 2015 | 39 | 0.520 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.520 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 50 | 0.510 |
Why?
| | Myocardial Infarction | 3 | 2018 | 960 | 0.510 |
Why?
| | Retrospective Studies | 19 | 2022 | 12823 | 0.500 |
Why?
| | Biomedical Research | 1 | 2020 | 596 | 0.490 |
Why?
| | Research Design | 1 | 2020 | 962 | 0.480 |
Why?
| | Middle Aged | 25 | 2021 | 27170 | 0.470 |
Why?
| | Registries | 2 | 2020 | 1788 | 0.470 |
Why?
| | Loperamide | 2 | 2023 | 10 | 0.460 |
Why?
| | United States Food and Drug Administration | 4 | 2016 | 173 | 0.460 |
Why?
| | Diet | 1 | 2021 | 1128 | 0.450 |
Why?
| | Male | 35 | 2022 | 56660 | 0.450 |
Why?
| | Myocardium | 3 | 2017 | 944 | 0.450 |
Why?
| | Precision Medicine | 6 | 2024 | 356 | 0.450 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 149 | 0.440 |
Why?
| | Muscle Proteins | 1 | 2015 | 218 | 0.440 |
Why?
| | Quality Improvement | 2 | 2020 | 956 | 0.440 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2038 | 0.430 |
Why?
| | Legislation, Medical | 1 | 2012 | 9 | 0.430 |
Why?
| | Peripartum Period | 4 | 2022 | 9 | 0.420 |
Why?
| | Adult | 26 | 2022 | 31003 | 0.420 |
Why?
| | Amiodarone | 1 | 2012 | 23 | 0.420 |
Why?
| | Patient Readmission | 1 | 2018 | 613 | 0.420 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 105 | 0.400 |
Why?
| | Catheter Ablation | 1 | 2015 | 282 | 0.400 |
Why?
| | Heart Arrest | 4 | 2019 | 289 | 0.390 |
Why?
| | Postoperative Complications | 2 | 2020 | 2198 | 0.390 |
Why?
| | Pyrazines | 2 | 2008 | 71 | 0.390 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 1782 | 0.390 |
Why?
| | Hospital Mortality | 5 | 2022 | 795 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2021 | 9256 | 0.380 |
Why?
| | Transfusion Reaction | 1 | 2011 | 38 | 0.370 |
Why?
| | Triazoles | 2 | 2008 | 126 | 0.370 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 486 | 0.370 |
Why?
| | Patient Transfer | 1 | 2012 | 144 | 0.360 |
Why?
| | Databases, Factual | 5 | 2020 | 1167 | 0.360 |
Why?
| | Insurance, Health | 1 | 2012 | 247 | 0.360 |
Why?
| | Patient Discharge | 2 | 2021 | 784 | 0.360 |
Why?
| | Ventricular Function, Left | 4 | 2022 | 470 | 0.360 |
Why?
| | Anemia | 1 | 2011 | 145 | 0.340 |
Why?
| | Risk Factors | 8 | 2020 | 8873 | 0.330 |
Why?
| | Thiazolidinediones | 1 | 2010 | 145 | 0.330 |
Why?
| | Marketing | 1 | 2008 | 24 | 0.330 |
Why?
| | Renal Insufficiency | 1 | 2011 | 147 | 0.330 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 17 | 0.320 |
Why?
| | Genotype | 3 | 2024 | 1854 | 0.320 |
Why?
| | Simvastatin | 1 | 2008 | 61 | 0.320 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 43 | 0.310 |
Why?
| | Heart Ventricles | 4 | 2017 | 728 | 0.310 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 53 | 0.310 |
Why?
| | Electrocardiography | 4 | 2019 | 548 | 0.310 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1105 | 0.300 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 25 | 0.300 |
Why?
| | Drug Industry | 1 | 2008 | 104 | 0.300 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 825 | 0.300 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 250 | 0.300 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1191 | 0.300 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2013 | 69 | 0.290 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1835 | 0.280 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 156 | 0.280 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 103 | 0.270 |
Why?
| | Young Adult | 9 | 2022 | 10674 | 0.260 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2408 | 0.260 |
Why?
| | Cause of Death | 2 | 2019 | 369 | 0.260 |
Why?
| | Ventricular Remodeling | 2 | 2017 | 234 | 0.250 |
Why?
| | Phenotype | 3 | 2020 | 2891 | 0.250 |
Why?
| | Pregnancy | 6 | 2022 | 5653 | 0.250 |
Why?
| | Glucose | 1 | 2010 | 931 | 0.250 |
Why?
| | Pandemics | 3 | 2022 | 1354 | 0.240 |
Why?
| | Incidence | 4 | 2021 | 2377 | 0.240 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 690 | 0.240 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 381 | 0.240 |
Why?
| | Adolescent | 10 | 2020 | 18213 | 0.240 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6453 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1233 | 0.240 |
Why?
| | Sex Factors | 3 | 2019 | 1758 | 0.230 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.230 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 686 | 0.230 |
Why?
| | Prognosis | 5 | 2020 | 3390 | 0.220 |
Why?
| | Medicare | 2 | 2020 | 668 | 0.210 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 67 | 0.210 |
Why?
| | Naltrexone | 1 | 2023 | 80 | 0.210 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1035 | 0.210 |
Why?
| | Time Factors | 3 | 2020 | 6240 | 0.200 |
Why?
| | Insulin Resistance | 1 | 2010 | 1162 | 0.200 |
Why?
| | Referral and Consultation | 2 | 2017 | 640 | 0.190 |
Why?
| | Smartphone | 1 | 2021 | 68 | 0.190 |
Why?
| | Red Meat | 1 | 2021 | 13 | 0.190 |
Why?
| | Hypertension | 2 | 2020 | 1179 | 0.190 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 34 | 0.190 |
Why?
| | Losartan | 1 | 2020 | 10 | 0.190 |
Why?
| | Actigraphy | 1 | 2021 | 83 | 0.190 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 327 | 0.190 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 21 | 0.190 |
Why?
| | Lisinopril | 1 | 2020 | 14 | 0.190 |
Why?
| | Speech | 1 | 2021 | 75 | 0.190 |
Why?
| | Protective Factors | 1 | 2021 | 88 | 0.190 |
Why?
| | Angioedema | 1 | 2020 | 17 | 0.190 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 38 | 0.190 |
Why?
| | American Heart Association | 2 | 2019 | 267 | 0.190 |
Why?
| | Software | 2 | 2015 | 557 | 0.190 |
Why?
| | Turner Syndrome | 1 | 2021 | 51 | 0.180 |
Why?
| | Biological Products | 1 | 2023 | 176 | 0.180 |
Why?
| | Data Accuracy | 1 | 2020 | 52 | 0.180 |
Why?
| | California | 2 | 2012 | 366 | 0.180 |
Why?
| | Social Determinants of Health | 1 | 2022 | 132 | 0.180 |
Why?
| | Milk | 1 | 2021 | 127 | 0.180 |
Why?
| | Bionics | 1 | 2019 | 11 | 0.180 |
Why?
| | Editorial Policies | 1 | 2020 | 44 | 0.180 |
Why?
| | Medical Futility | 1 | 2019 | 19 | 0.180 |
Why?
| | Medical Informatics | 1 | 2020 | 94 | 0.180 |
Why?
| | Medical Record Linkage | 1 | 2020 | 55 | 0.170 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 111 | 0.170 |
Why?
| | Drug Overdose | 1 | 2023 | 293 | 0.170 |
Why?
| | Echocardiography | 2 | 2019 | 564 | 0.170 |
Why?
| | Prescription Drugs | 1 | 2020 | 112 | 0.170 |
Why?
| | Cohort Studies | 3 | 2021 | 5050 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2021 | 241 | 0.160 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 30 | 0.160 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 238 | 0.160 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 42 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1889 | 0.160 |
Why?
| | Tobacco Use | 1 | 2019 | 60 | 0.160 |
Why?
| | Child Health Services | 1 | 2020 | 176 | 0.160 |
Why?
| | Computer Graphics | 2 | 2015 | 45 | 0.160 |
Why?
| | Cluster Analysis | 1 | 2019 | 478 | 0.160 |
Why?
| | Prospective Studies | 4 | 2021 | 6389 | 0.150 |
Why?
| | Advisory Committees | 1 | 2019 | 208 | 0.150 |
Why?
| | Florida | 1 | 2018 | 76 | 0.150 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 8 | 0.150 |
Why?
| | Length of Stay | 3 | 2021 | 989 | 0.150 |
Why?
| | Forecasting | 1 | 2019 | 335 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4507 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2019 | 159 | 0.150 |
Why?
| | Academic Medical Centers | 1 | 2020 | 415 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 434 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 406 | 0.140 |
Why?
| | Nursing Assessment | 1 | 2017 | 46 | 0.140 |
Why?
| | Patient Participation | 1 | 2020 | 367 | 0.140 |
Why?
| | Consensus | 1 | 2019 | 532 | 0.140 |
Why?
| | Pressure Ulcer | 1 | 2017 | 32 | 0.140 |
Why?
| | Cardiology | 1 | 2019 | 262 | 0.140 |
Why?
| | Heart Diseases | 1 | 2020 | 336 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 102 | 0.140 |
Why?
| | Tilidine | 1 | 2016 | 1 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 338 | 0.130 |
Why?
| | Oxycodone | 1 | 2016 | 43 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2017 | 212 | 0.130 |
Why?
| | Computational Biology | 2 | 2017 | 540 | 0.130 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 6 | 0.130 |
Why?
| | Sex Distribution | 1 | 2016 | 331 | 0.130 |
Why?
| | Rheumatic Fever | 1 | 2015 | 8 | 0.130 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 32 | 0.130 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 17 | 0.130 |
Why?
| | Marijuana Use | 1 | 2018 | 160 | 0.130 |
Why?
| | Naloxone | 1 | 2016 | 96 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1588 | 0.130 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 22 | 0.130 |
Why?
| | Angiotensin II | 1 | 2015 | 107 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 40 | 0.120 |
Why?
| | United Kingdom | 1 | 2015 | 233 | 0.120 |
Why?
| | Mothers | 1 | 2020 | 682 | 0.120 |
Why?
| | Heart Rate | 2 | 2022 | 708 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 450 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 761 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 2950 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2015 | 117 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1487 | 0.120 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 135 | 0.120 |
Why?
| | Chronic Disease | 2 | 2020 | 1619 | 0.120 |
Why?
| | Cholesterol | 1 | 2015 | 371 | 0.110 |
Why?
| | Gene Expression | 2 | 2017 | 1466 | 0.110 |
Why?
| | MicroRNAs | 2 | 2017 | 627 | 0.110 |
Why?
| | Down-Regulation | 1 | 2015 | 606 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 366 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 639 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2017 | 2632 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 472 | 0.110 |
Why?
| | Federal Government | 1 | 2012 | 26 | 0.110 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 102 | 0.100 |
Why?
| | Drug Resistance | 1 | 2012 | 166 | 0.100 |
Why?
| | Area Under Curve | 1 | 2012 | 285 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1824 | 0.100 |
Why?
| | Colorado | 4 | 2024 | 4120 | 0.100 |
Why?
| | Patient Safety | 1 | 2015 | 278 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2227 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 102 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3549 | 0.100 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 342 | 0.100 |
Why?
| | Survival Rate | 1 | 2015 | 1679 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 206 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2012 | 341 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 930 | 0.090 |
Why?
| | Double-Blind Method | 2 | 2012 | 1670 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1114 | 0.090 |
Why?
| | Managed Care Programs | 2 | 2022 | 134 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 207 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1314 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2017 | 851 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2633 | 0.080 |
Why?
| | Primary Health Care | 1 | 2019 | 1508 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1458 | 0.080 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 34 | 0.080 |
Why?
| | Drug Approval | 1 | 2008 | 76 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 588 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2010 | 311 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 1877 | 0.070 |
Why?
| | Animals | 3 | 2023 | 32736 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 160 | 0.070 |
Why?
| | Zimbabwe | 2 | 2017 | 42 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 426 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 243 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 965 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3099 | 0.060 |
Why?
| | Depression | 2 | 2022 | 1137 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1689 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4510 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 123 | 0.060 |
Why?
| | Mandible | 1 | 2004 | 64 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 38 | 0.060 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 35 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 723 | 0.060 |
Why?
| | Algorithms | 3 | 2020 | 1505 | 0.050 |
Why?
| | Child | 5 | 2020 | 18876 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 36 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 80 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 112 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 4 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 171 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 224 | 0.050 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 12 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2022 | 196 | 0.050 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 23 | 0.050 |
Why?
| | Health Services Misuse | 1 | 2020 | 36 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 439 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 283 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 1941 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 450 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 29 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 37 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 658 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 195 | 0.040 |
Why?
| | Bias | 1 | 2020 | 193 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2446 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 1993 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 221 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 309 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 379 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 541 | 0.040 |
Why?
| | Focus Groups | 1 | 2019 | 387 | 0.040 |
Why?
| | Neoplasms | 1 | 2010 | 2146 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1106 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 101 | 0.030 |
Why?
| | Pharmacovigilance | 1 | 2016 | 13 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 107 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 474 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 173 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 331 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 31 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 105 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 291 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 82 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 99 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1618 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1056 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2818 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 979 | 0.030 |
Why?
| | Mass Screening | 2 | 2013 | 1034 | 0.030 |
Why?
| | Infant | 2 | 2015 | 8121 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 587 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 9322 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 41 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 90 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 4606 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 82 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 957 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 191 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 827 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2433 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 208 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 105 | 0.020 |
Why?
| | Mice | 1 | 2023 | 15308 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 671 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 376 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 667 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 481 | 0.020 |
Why?
| | Hospitals, University | 1 | 2005 | 168 | 0.020 |
Why?
| | Dentists | 1 | 2004 | 20 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1271 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 66 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 57 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 226 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 149 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 21 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1239 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 444 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 577 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1206 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 920 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2032 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2817 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 781 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|